Table 2.
Clinical and therapeutic characteristics of the study population
| UC (N=187) | CD (N=182) | p-value | |
|---|---|---|---|
| Disease duration (year) | 8.98±7.70 | 9.28±5.39 | 0.138 |
| Disease activity | <0.001* | ||
| Remission | 104 (55.61) | 43 (23.63) | |
| Mild | 54 (28.88) | 82 (45.05) | |
| Moderate to severe | 29 (15.51) | 57 (31.32) | |
| Presence of comorbidity | 7 (3.72) | 9 (4.92) | 0.571 |
| DM | 2 (1.07) | 3 (1.65) | 0.682 |
| Malignancy | 3 (1.60) | 3 (1.65) | 1.000 |
| Liver disease | 2 (1.07) | 1 (0.55) | 1.000 |
| Cerebrovascular accident | 0 | 1 (0.55) | 0.493 |
| Myocardial infarction | 0 | 2 (1.10) | 0.243 |
| Others (CHF, COPD, AIDS, dementia, peripheral vascular disease) | 0 | 0 | |
| Current treatment | |||
| 5-aminosalicylic acid | 174 (93.05) | 144 (79.12) | <0.001* |
| Immunosuppressant (azathiopurine, 6-MP, MTX) | 84 (44.92) | 113 (62.09) | <0.001* |
| Steroid | 9 (4.81) | 6 (3.30) | 0.461 |
| Anti-TNF alpha (infliximab, adlimumab, golimumab) | 35 (18.72) | 124 (68.13) | <0.001* |
| Others (filgotinib, tofacitinib, ustekinumab, vedolizumab) | 30 (16.04) | 11 (6.04) | 0.002* |
| Number of IBD-related hospitalizations | 0.78±1.34 | 1.51±1.83 | <0.001* |
| Number of IBD-related surgeries | 0.06±0.42 | 0.60±0.89 | <0.001* |
| History of steroid use | 114 (60.96) | 129 (70.88) | 0.037* |
| History of biologics use | 63 (33.69) | 115 (63.19) | <0.001* |
| History of treatment discontinuation | 2 (1.07) | 11 (6.04) | 0.010* |
Data are presented as mean±SD or number (%).
*
p<0.05.
UC: ulcerative colitis, CD: Crohn’s disease, IBD: inflammatory bowel disease